Sellas Life Sciences is trading at $11.88, up 4.90%, alongside a broad market advance as weak September payrolls supported a risk-on response. - Payrolls rose 29,000 versus 84,000 expected; investors anticipated less pressure for Fed rate hikes. - S&P 500: +0.99%; Nasdaq: +1.56%; Dow: +0.62%. - An October 2 article covered late-September SLS009 preclinical findings but did not link them to the move; intraday volume was not provided.